Alpha-1 Foundation Celebrates Three Decades of Advancements in Deficiency Care and Research
Celebrating 30 Years of the Alpha-1 Foundation
The Alpha-1 Foundation (A1F) proudly celebrates three decades of dedicated service and advancements in the treatment and understanding of Alpha-1 Antitrypsin Deficiency. Founded on January 31, 1995, by three passionate patients, John W. Walsh, Sandy Lindsey, and Susan Stanley, A1F emerged from the realization that further resources were necessary to address the needs of those affected by this rare genetic condition.
The Impact of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (commonly referred to as Alpha-1) is an inherited disorder that can lead to severe lung and liver diseases. The journey towards finding effective treatments has been fraught with challenges, but A1F has been at the forefront of this battle, advocating for patients and facilitating groundbreaking research.
From its inception, A1F has committed itself to improving patients' lives by investing over $100 million in research at 130 institutions across North America, Europe, the Middle East, and Australia. This extensive investment has spurred innovative developments and significant strides in understanding the disease.
Patient-Centric Approach
What sets A1F apart is its patient-driven framework. The foundation was established and continues to be managed by individuals who are either living with Alpha-1 or have a direct connection to the condition through family members. This unique perspective has enabled A1F to design programs that resonate with the needs and experiences of the Alpha-1 community.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.